novo nordisk

Latest news and analysis on novo nordisk

Equities

The appetite suppressant: how to invest in the world’s obsession with weight-loss

More than 20 million people globally are injecting themselves with GLP-1s... Weight-loss pills will only see that explode further.
Arms Rosenberg
Minotaur Capital
Education

The “iPhone moment” for obesity treatment

In early March, Novo Nordisk held its Capital Markets Day which we attended virtually. Quite unusually, the day kicked off with the CEO interviewing a former obesity...
Ted Franks
Pengana Capital Group
Funds

The weight is over: obesity drugs have arrived

Breakthroughs in obesity drugs look extraordinarily profitable for 2 stocks. But, with improvements, a raft of sectors might be affected.
Damien Klassen
Nucleus Wealth
Education

Ozempic – Is Novo Nordisk’s diabetes and weight loss drug a miracle or a menace?

In a society riddled with low self-esteem and mental health issues, weight loss can be a controversial and difficult topic. Pop culture and social media do more harm...
Ted Franks
Pengana Capital Group
4